Effect of Long-Acting Thromboxane Receptor Antagonist (BMS 180,291) on Experimental Antiphospholipid Syndrome

Abstract

Antiphospholipid syndrome (APS) is characterized by recurrent thromboembolic phenomena, recurrent fetal loss and thrombocytopenia associated with high titers of IgG anticardiolipin antibodies and/or lupus anticoagulant. There is an increased platelet aggregation in these patients and thus aspirin was found to be effective in abrogating some of the clinical findings.

The purpose of this study was to employ the experimentally induced APS in mice infused with anticardiolipin antibodies, to study the effect of a thromboxane receptor antagonist (BMS, 180, 291) on the various overt manifestations of APS.

Experimental APS was induced in pregnant female mice by iv infusion of a pathogenic anticardiolipin antibody (CAM). The mice were then treated daily with 300 μg/mouse of BMS. The study group and the untreated group were killed on day 17 of pregnancy. Live and absorbed fetuses and the mean weight of the placentae, fetuses and platelet counts were recorded.

BMS treated mice had a significant reduction in fetal resorption rate from 45% to 19.8% and an increase in mean placental and embryo weights (182 vs 104, 1043 vs 721 mg, respectively). In parallel, an increase in platelet count (from 597 100 to 1075 000 platelets/mm³) and decrease in activated thromboplastin time (95 to 44 s) was seen.

It seems that thromboxane receptor antagonist may be effective in abrogating the diverse manifestations seen in APLS. Increased platelet aggregation may be one of the pathogenetic mechanisms in APS.

Keywords

Antiphospholipid syndrome Platelet aggregation Thromboxane

Get full access to this article

View all access options for this article.

References

Asherson RA , Khamashta MA , Ordi-Ros J. et al. The 'primary' antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore) 1989; 68: 366-74.

Sammaritano LR , Gharavi AE , Lockshin MD Antiphospholipid antibody syndrome: immunologic and clinical aspects. Semin Arthritis Rheum 1990; 20: 81-96.

Alarcon-Segovia D. , Sanchez-Guerrero J. Primary antiphospholipid syndrome. J Rheumatol 1989 ; 16: 482-8.

Blank M. , Cohen J. , Toder V. , Shoenfeld Y. Induction of antiphospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anticardiolipin antibodies, proc Natl Acad Sci USA 1991; 88: 3069-73.

Bakimer R. , Fishman P. , Blank M. , Sredni B. , Djaldetti M. , Shoenfeld Y. Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anti-cardiolipin antibody (H-3). J Clin Invest 1992; 89: 1558-663.

Branch DW , Scott JR , Kochenour NK , Hershgold E. Obstetric complications associated with the lupus anticoagulants. New Engl J Med 1985; 313: 1322-6.

DeWolf F. , Carreras LO , Moerman P. , Vermylen J. , Van Assche A. , Renaer M. Decidual vasculopathy and extensive placental infarction in a patient with repeated thromboembolic accidents, recurrent fetal loss and a lupus anticoagulant . Am J Obstet Gynecol 1982 ; 142: 829-34.

Carrerare LO , Defreyn G. , Machin SJ , Vermylen J. , Deman R. , Spitz B. , van Assche A. Arterial thrombosis intrauterine death and 'lupus' anticoagulant: detection of immunoglobulin interfering with prostacyclin formation. Lancet 1981; 1: 244-6.

Marchesi D. , Parbtani A. , Frampton G. , Livio M. , Remuzzi G. , Cameron JS Thrombotic tendency in systemic lupus erythematosus. Lancet 1981; 1: 719.

10.

Out HJ , de Groot PG , van Vliet M. , de Gast GC , Nieuwenhu HK , Derksen Rhwm. Antibodies to platelet in patients with antiphospholipid antibodies . Blood 1991; 77: 2655-60.

11.

Khamashta MA , Harris EN , Gharavi AE et al. Immune mediates mechanism for thrombosis: antiphospholipid antibody binding to platelet membranes . Ann Rheum Dis 1988; 47: 849-53.

12.

Martinazzo ME , Maclouf J. , Carreras LO , Levy-toledano S. Antiphospholipid antibodies enhance thrombin induced platelet activation and thromboxane formation . Thromb Haemostas 1993; 70: 667-71.

13.

Fitzgerals GA , Oates JA , Hawiger J. et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest 1983; 71: 676-88.

14.

Vane JR Inhibition of prostaglandin synthesis as a mechanism of action by aspirin-like drugs. Nature (New Biology) 1971 ; 231: 232-5.

15.

Blank M. , Krause I. , Ben-Bassat M. , Shoenfeld Y. Induction of experimental antiphospholipid syndrome associated with SLE following immunization with human monoclonal pathogenic anti-DNA idiotype . J Autoimmunity 1992; 5: 495-509.

16.

Shoenfeld Y. Induction of experimental primary and secondary anti-phospholipids syndrome in naive mice. Am J Reproduct Immunol 1992; 28: 219-22.

17.

Krause I. , Blank M. , Gulburd B. , Shoenfeld Y. The effect of aspirin on recurrent fetal loss in experimental antiphospholipid syndrome. Am J Reproduct Immunol 1993; 29: 155-61.

18.

Fishman P. , Falach-Vaknine E. , Zilegman R. et al. Prevention of fetal loss in experimental antiphospholipid syndrome by in vivo administration of recombinant interleukin-3. J Clin Invest 1993 ; 91: 1834—9.

19.

Inbar O. , Blank M. , Faden D. , Tincani A. , Lorber M. , Shoenfeld Y. Prevention of fetal loss in experimental antiphospholipid syndrome by low molecular weight heparin. Am J Obstet Gynecol 1993; 169: 423-6.

20.

Bakimer R. , Guilbrud B. , Zurgil N. , Shoenfeld Y. The effect of intravenous γ-globulin on the induction of experimental antiphospholipid syndrome. Clin Immunol Immunopathol 1993; 69: 97-102.

21.

Ogletree ML , Harris DN , Schumacher WA , Wemm ML , Misra RN Pharmacological profile of BMS 180,291: a potent, long-acting, orally active thromboxane A2/prostaglandin endoperoxide receptor antagonist. J Pharmacol Exp Therapeut 1992; 264: 570-8.

22.

Schumacher WA , Steinbacher TE , Youssef S. , Ogletree ML Antiplatelet activity of the long-active thromboxane receptor antagonist BMS 180,291 in monkeys. Prostaglansins 1992; 44: 389-97.

23.

Ogletree ML , O'Keefe EH , Durham SK , Rubin B. , Aberg G. Gastroprotective effects of thromboxane receptor antagonists. J Pharmacol Exp Therapeut 1992 ; 263: 374-80.

24.

Whittle Bjr. Mechanisms underlying gastric mucosal damage induced by indomethacin and bile salts; and the actions of prostaglandins . Br J Pharmacol 1977; 60: 455-60.

25.

DI Renzo GC , Coata G. , Franceschi SD et al. Platelet thromboxane A2 receptor number and function in normal and hypertension pregnancy. Am J Reprod Immunol 1993; 30: 160-6.